These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 37079651)

  • 1. Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses.
    Wang CY; Peng WJ; Kuo BS; Ho YH; Wang MS; Yang YT; Chang PY; Shen YH; Hwang KP
    PLoS Pathog; 2023 Apr; 19(4):e1010870. PubMed ID: 37079651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants.
    Wang CY; Hwang KP; Kuo HK; Peng WJ; Shen YH; Kuo BS; Huang JH; Liu H; Ho YH; Lin F; Ding S; Liu Z; Wu HT; Huang CT; Lee YJ; Liu MC; Yang YC; Lu PL; Tsai HC; Lee CH; Shi ZY; Liu CE; Liao CH; Chang FY; Chen HC; Wang FD; Hou KL; Cheng J; Wang MS; Yang YT; Chiu HC; Jiang MH; Shih HY; Shen HY; Chang PY; Lan YR; Chen CT; Lin YL; Liang JJ; Liao CC; Chou YC; Morris MK; Hanson CV; Guirakhoo F; Hellerstein M; Yu HJ; King CC; Kemp T; Heppner DG; Monath TP
    J Clin Invest; 2022 May; 132(10):. PubMed ID: 35316221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease.
    Wang CY; Kuo BS; Lee YH; Ho YH; Pan YH; Yang YT; Chang HC; Fu LF; Peng WJ
    iScience; 2024 Feb; 27(2):108887. PubMed ID: 38318376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
    Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L
    Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.
    Wang S; Wang CY; Kuo HK; Peng WJ; Huang JH; Kuo BS; Lin F; Liu YJ; Liu Z; Wu HT; Ding S; Hou KL; Cheng J; Yang YT; Jiang MH; Wang MS; Chen T; Xia WG; Lin E; Hung CH; Chen HJ; Shih Z; Lin YL; Ryan V; Hu MM; Heppner DG; Malherbe DC; Periasamy S; Kuzmina N; Subramani C; Hellerstein M; Monath TP; Rumyantsev A; Bukreyev A; Guirakhoo F
    Emerg Microbes Infect; 2022 Dec; 11(1):2724-2734. PubMed ID: 36287714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults.
    Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA
    Front Immunol; 2022; 13():882918. PubMed ID: 35958601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E
    Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine.
    Huang R; Ying L; Wang J; Xia J; Zhang Y; Mao H; Zhang R; Zang R; Le Z; Shu Q; Xu J
    Front Immunol; 2023; 14():1139620. PubMed ID: 37114058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.
    Yi X; Wang Y; Li Q; Li X; Zhang P; Fu X; Gu S; Zhang D; Liu X; Lou H; Wu Y; Tang L; Hou J; Li Y
    J Med Virol; 2023 Mar; 95(3):e28642. PubMed ID: 36890630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.